论文部分内容阅读
慢性乙型肝炎的致病机理极为复杂。当前尚缺少特效药物治疗。目前大多数学者认为,慢性乙型肝炎迁延不愈的主要原因,系病毒长期持续在体内存在。并且发病机理可能与病毒株的毒力,受感染肝细胞的数量和病人免疫系统的反应等诸因素有关,例如:慢性乙型肝炎患者血清或肝细胞中的乙型肝炎病毒(HBV)复制标志(HEeAg、DNA多聚酶、抗HBc—IgM、HBV—DNA、HBcAg等)均可长久存在,并能造成肝脏和其他脏器的病变。为此,应用抗病毒药物为治疗本病的首要措施。并在部分病例的应用中已见成效,现将慢性乙肝抗病毒药物治疗进展综述如下。一、干扰素诱导剂(Interferon inducer) 有些诱导荆,侧如聚肌苷酸聚胞苷酸(简称聚肌胞Polyl:C),聚肌苷酸聚尿苷酸(PolyA:U)等均
The pathogenesis of chronic hepatitis B is extremely complex. Currently there is a lack of effective drug treatment. At present, most scholars believe that the main reason for delayed healing of chronic hepatitis B is that the virus persists in the body for a long time. And the pathogenesis may be related to the virulence of the virus strains, the number of infected liver cells and the patient’s immune system response and other factors, such as: hepatitis B virus (HBV) replication markers in serum or liver cells of patients with chronic hepatitis B (HEeAg, DNA polymerase, anti-HBc-IgM, HBV-DNA, HBcAg, etc.) can persist for a long time and cause lesions in the liver and other organs. To this end, the application of antiviral drugs for the treatment of this disease the primary measures. And in some cases the application has been successful, now the progress of treatment of chronic hepatitis B antiviral drugs are summarized below. First, interferon inducer (Interferon inducer) Some induced Jing, side as polygonin cytoplasmic polyglycosidase (referred to polyglobulin Polyl: C), poly inosinic acid poly (UA) and so on